Navigation Links
UW-Madison has 7 Sloan research fellows, top in nation

The University of Wisconsin-Madison leads the nation in the number of Sloan Foundation Fellowships in Science and Technology awarded in 2006. UW-Madison's total this year is up to seven, from the two Sloans awarded in 2005.

The foundation bestows the awards on young researchers in the fields of chemistry, computer science, economics, mathematics, molecular biology, neuroscience and physic......

Full article >>>
'"/>

Source:wistechnology.com By Barbara Wolff 03/20/06


Page: 1 2

Related biology technology :

1. UW-Madison to receive $125M for bioenergy research center
2. Three finalists named for UW-Madison CIO
3. UW-Madison launches new high-speed research network
4. UW-Madison approves new research institute
5. UW-Madison dean predicts bio-economy will fuel Wisconsin
6. Scott Converse, UW-Madison School of Business, on the innovation mind-set
7. Scott Converse, UW-Madison School of Business, on IT workforce development
8. UW-Madisons Beebe wins scientific award
9. UW-Madison MBA program ranked among best for investment return
10. UW-Madison gets $333,000 for biofuels research
11. UW-Madison enters Kauffman grant competition
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Madison has Sloan research fellows top nation

Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2